The percentage of tumor cells overexpressing CD155 was 17%, 39%, 37%, and 62% among Luminal A, Luminal B, HER2-positive, and TNBC cases, respectively (p < 0.05, Figure 2). This evidence concerns the gene PVR and neoplasm.